SVNS.LSE

Solvonis Therapeutics plc

SVNS.LSE, UK

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product candidate includes SVN-SDN-14 for the treatment of post-traumatic stress disorder. The company was formerly known as Graft Polymer (UK) Plc and changed its name to Solvonis Therapeutics plc in January 2025. Solvonis Therapeutics plc was incorporated in 2017 and is headquartered in London, the United Kingdom.

https://solvonis.com

Stock Price

GBp 0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SVNS.LSE
stock
SVNS.LSE

FTSE 100 Live: London stocks spooked lower as October winds up Proactive Investors

Read more →
SVNS.LSE
stock
SVNS.LSE

Appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth Investing News Network

Read more →

Showing 2 of 8

Analyst Ratings & Sentiment

(Last Updated 2024-12-31)

Rating:

BUY

$

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2024-12-31)

Health Score

Price to Book Ratio (P/B)

-

Very High

11.29

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-10.86 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-10.46 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.04

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Solvonis Therapeutics plc

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-06-30

EPS Actual

-0.0006

EPS Estimate

0

EPS Difference

-0.0006

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2024-12-31)

Deep Value
Weak Deep Value(2.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(2.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2024-12-31)

Revenue

ÂŁ 0

Cost Of Revenue

ÂŁ 0

Gross Profit

ÂŁ 0

Operating Expenses

ÂŁ 0

Operating Income

ÂŁ 0

Interest Expense

ÂŁ 0

Pretax Income

ÂŁ 0

Net Income

ÂŁ 0

Income Tax Expense

ÂŁ 0

EBITDA

ÂŁ 0

Total Other Income Expense Net

ÂŁ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2024-12-31)

Cash

ÂŁ 0

Short Term Investments

ÂŁ 0

Receivables

ÂŁ 0

Inventories

ÂŁ 0

Total Current Assets

ÂŁ 0

Property Plant Equipment

ÂŁ 0

Total Assets

ÂŁ 0

Payables

ÂŁ 0

Short Term Debt

ÂŁ 0

Long Term Debt

ÂŁ 0

Total Liabilities

ÂŁ 0

Equity

ÂŁ 0

Trend

Cash Flow

(Last Updated 2024-12-31)

Net Income

ÂŁ 0

Depreciation

ÂŁ 0

Change In Working Capital

ÂŁ 0

Cash From Operations

ÂŁ 0

Capital Expenditures

ÂŁ 0

Cash From Investing

ÂŁ 0

Cash From Financing

ÂŁ 0

Net Change In Cash

ÂŁ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.